Who We Are

Nexus Medical, LLC began in 2000 when the U.S. Army Medical Material Command in Fort Detrick Maryland awarded a grant to research unintentional blood reflux into IV catheters and prevent the many unintended consequences it caused the Warfighters.

Nexus Medical’s engineers learned blood reflux was caused by a multiplicity of physiological (internal) and mechanical (external) pressure fluctuations in the patient’s closed IV system.

Nexus Medical’s engineers studied the human factors associated with internal and external pressures causing blood reflux into peripheral IV catheters, midlines, PICC and CV catheters.

Nexus Medical submitted the first FDA 510K for both a pre-slit septum needleless connector and a luer activated needleless connector with pressure activated anti-reflux diaphragm. We called the new anti-reflux needleless connector TKO (“To Keep Open”).

The first clinical trials for the Nexus TKO-1 were conducted at Wilford Hall Medical Center, San Antonio, Texas, in the bone marrow transplant unit.

While using the Nexus TKO®-5 on PICC and CVC lines, Wesley Medical Center reduced occlusion and tPA/alteplase consumption by 71% and eliminated Heparin maintenance flushing.

FDA 510K cleared the first anti-reflux pressure-rated microbore and standard bore extension sets.

Study published in the Journal of Infusion Nursing shows fewer occlusions and decreased costs when using the TKO needleless connector compared to a neutral connector.

Nexus Medical received FDA 510K clearance on the first luer-activated TKO anti-reflux technology and launched the TKO®-6.

Nexus Medical receives FDA 510K clearance and launches a complete line of neonatal and pediatrics infusion extension sets, blood gas sampling sets, bi-, tri-, and quad-furcated extension sets and manifold sets.

Nexus TKO®-6P received FDA 510K clearance and Nexus Medical launched the pressure-rated version of the luer-activated TKO anti-reflux technology.

Nexus introduces the TKO 6P-HV (High Visibility) needleless connector and extension sets for home infusion therapy patients.

Study demonstrates that TKO has the least amount of reflux compared to 14 commercially available needleless connectors (published in the Journal of Vascular Access)

Research demonstrates a 69% reduction in occlusions using TKO compared to a neutral connector (published in the Journal of Association of Vascular Access).

Study published in the Journal of the Association of Vascular Access demonstrates that TKO has the least of amount of reflux and bi-directional flow control compared to 13 commercially available needleless connectors.

2021 Infusion Therapy Standards of Practice (8th edition) notes that anti-reflux needleless connectors designed with a bidirectional, pressure-sensitive diaphragm require no specific clamping sequence and offer the least amount of blood reflux.